UBI集團訊息
Former Area Head of North Asia Clinical Management of PPD to join United BioPharma
PJ Chen is highly experienced in clinical trial management, clinical strategy planning and business operations and has served in as several critical positions in the pharmaceutical industry, including VP of Clinical development and President of UNS (Taiwan), Executive Director & Area Head of North Asia Clinical Management of PPD (Shanghai), Executive Director of Project management and Commercial Operation of WuXiPRA (Shanghai), leader of Respiratory/GI portfolio Global medicine Development of AstraZeneca (Shanghai), Project Leader of PAREXEL International (Taipei/Shanghai), Group Manager of Study management and operation of AstraZeneca (Shanghai). He received his Master’s degree in Biomedical Imaging area from Massachusetts Institute of Technology, USA,.
PJ Chen’s expertise and experience in clinical development and business operations, will facilitate the global clinical development and commercialization of UBP’s product pipeline.
About United BioPharma (6471)
UBP was established in September 2013 as a spinoff from United Biomedical, Inc., Asia, and is strategically partnering with Formosa Plastics Group. UBP has an integrated monoclonal antibody drug development platform, and focuses on development, manufacturing, and marketing of innovative monoclonal antibody drugs and biosimilars. With a spirit of “innovation and practicality,” UBP is dedicated to addressing unmet medical needs of mankind.
United BioPharma Forward-Looking Statements
The information in this press release should be considered accurate only as of the date of the release. UBP has no intention of updating and specifically disclaims any duty to update the information in this press release. The press release may contain forward-looking statements involving risks and uncertainties and UBP’s actual results may differ materially from those in the forward-looking statements.